Abstract
International scientific bodies currently recommend the use of cardiac troponins for the detection of myocardial necrosis (1)(2). Some troponin assays, however, are inadequately appraised before their introduction in clinical use (3). The Committee on Standardization of Markers of Cardiac Damage (C-SMCD) of the IFCC proposed quality specifications for cardiac troponin assays with the objectives to help assay manufacturers and clinical laboratories and to urge the scientific community to select and design research projects on the major issues in troponin determination (4). The study by Uettwiller-Geiger et al. (5) published in this month’s issue of Clinical Chemistry represents a good example that fulfills these suggestions.